It has been demonstrated that continuous exposure of K562, a CML cell line, with imatinib which decreases glucose uptake and inactivates glycolytic enzymes, can lead to induction of autophagy in CML cells by mechanisms involving activation of AMPK and suppression of S6K1 (62). This evidence concerns the gene RPS6KB1 and chronic myelogenous leukemia, BCR-ABL1 positive.